CYBN Cybin Inc

16
Price
$0.20
Decreased by -0.45%
Dollar volume (20D)
1.56 M
ADR%
8.22
Shares float
574.01 M
Shares short
14.90 M [2.60%]
Shares outstanding
759.69 M
Market cap
159.08 M
Beta
0.92
Price/earnings
N/A
20D range
0.17 0.27
50D range
0.17 0.34
200D range
0.17 0.57

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.

The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.

The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers.

The company is headquartered in Toronto, Canada.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Jun 26, 24 0.00
Increased by +100.00%
-0.03
Increased by +100.00%
Feb 14, 24 -0.09
Decreased by -50.00%
-0.04
Decreased by -125.00%
Nov 13, 23 -0.05
Increased by +16.67%
-0.05
Aug 14, 23 -0.07
Increased by 0.00%
-0.06
Decreased by -16.67%
Jun 27, 23 -0.07
Increased by +30.00%
-0.06
Decreased by -16.67%
Feb 16, 23 -0.06
Increased by +40.00%
-0.06
Nov 14, 22 -0.06
Increased by +45.45%
-0.07
Increased by +14.29%
Aug 8, 22 -0.07
Increased by +22.22%
-0.09
Increased by +22.22%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 23 0.00
Decreased by N/A%
-30.33 M
Decreased by -182.35%
Decreased by N/A%
Decreased by N/A%
Sep 30, 23 0.00
Decreased by N/A%
-11.89 M
Decreased by -19.22%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by N/A%
-12.38 M
Increased by +5.21%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-13.72 M
Increased by +24.19%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-10.74 M
Increased by +37.58%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-9.97 M
Increased by +43.36%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-13.05 M
Increased by +11.29%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Increased by +100.00%
-18.10 M
Decreased by -31.35%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY